52-Week High & Low Stocks: CF, MGEE, ITC, AEO, AUO, UTHR
Wednesday, August 24, 2021 1:47 PM



Several stocks recorded a new 52-week high/low during the day when the US market traded in a flat note. Some notable stocks are discussed here.

Cf Industries Holdings, Inc. (NYSE: CF) recorded a new all-time high of $180.39 today, with a trading volume of more than 1.54 million shares. The stock is downgraded to Neutral from Buy by analysts at Chardan Capital Markets. Shares of Cf Industries were down 3.20 percent or $5.72 to trade at $173.23.

MGE Energy Inc. (Nasdaq: MGEE) hit a new 52-week high of $42.95 today, with a trading volume of 32 thousand shares. Recently, the company raised its dividend for the 36th consecutive year to $0.3826 per year on the company’s common stock. Shares added 0.88 percent or 37 cents to trade at $42.54.

ITC Holdings (NYSE: ITC) recorded a new all-time high of $74.86 with a trading volume of more than 173 thousand shares. The company appointed former US Representative J.C. Watts and former Governor of South Dakota M. Michael Rounds as independent directors to its board. Shares added 2.16 percent or $1.58 to trade at $74.78.

American Eagle Outfitters (NYSE: AEO) slipped to a new all-time low of $10.01 today, with a trading volume of more than 12.52 million shares. In its FY2011 Q2, the company reported net income of $19.66 million, 10 cents per share, up from $9.66 million or 5 cents per share a year earlier. The company registered net sales of $675.7 million, compared to net sales of $651.5 million a year ago. Shares were down 12.13 percent or $1.41 to trade at $10.21.

AU Optronics Corp. (NYSE: AUO) recorded a new 52-week low of $4.13 with a trading volume of 1.57 million shares today. Hewlett-Packard Co. (NYSE: HPQ) has accused AU Optronics of conspiring to fix prices of thin-film transistors liquid crystal display panels. Shares of AU Optronics fell 3.89 percent or 17 cents to trade at $4.20.

United Therapeutics Corp. (Nasdaq: UTHR) hit an all-time low of $38.87 with a trading volume of 10.42 million shares. The company announced that its blood pressure drug treprosrinil did not work better than a placebo in a late-stage clinical trial. Shares slumped 17.92 percent or $8.74 to trade at $40.02.

 


 

Sponsors

Advertisement


Advertisement